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Generally, solid tumors (>400 mm3) are inherently acidic, with
more aggressive growth producing greater acidity. If the acidity
could be targeted as a biomarker, it would provide a means to
gauge the pace of tumor growth and degree of invasiveness, as
well as providing a basis for predicting responses to pH-depen-
dent chemotherapies. We have developed a 64Cu pH (low) in-
sertion peptide (pHLIP) for targeting, imaging, and quantifying
acidic tumors by PET, and our findings reveal utility in assessing
prostate tumors. The new pHLIP version limits indiscriminate
healthy tissue binding, and we demonstrate its targeting of
extracellular acidification in three different prostate cancer models,
each with different vascularization and acid-extruding protein car-
bonic anhydrase IX (CAIX) expression. We then describe the tumor
distribution of this radiotracer ex vivo, in association with blood
perfusion and known biomarkers of acidity, such as hypoxia, lactate
dehydrogenase A, and CAIX. We find that the probe reveals meta-
bolic variations between and within tumors, and discriminates be-
tween necrotic and living tumor areas.
The rapid growth and division of tumor cells create an en-hanced need for glucose and other nutrients, which the
cells take up at a high rate, overwhelming their mitochondrial
capacity to use all of the glucose efficiently (1). The result is
aerobic glycolysis, which elevates lactate and proton pro-
duction: the “Warburg” effect (1, 2). Further, some tumors are
starved for oxygen, resulting in even more glycolytic acid
production (3, 4). Under the resulting low pH conditions,
normal cells have a tendency to undergo p53-induced apo-
ptosis (5, 6), whereas cancerous cells invoke alternative routes,
manipulating ion fluxes with proton extruders and other trans-
porters to afford continuous survival (7). Pumping the acidic
components out of the cell maintains cytoplasmic pH and
enhances the pH gradient (ΔpH), and the cellular exterior
surfaces become more acidic than those of cells in normal
tissues (8). The level of extracellular acidification, however, is
variable, depending on (i) the reliance of the malignancy on
glycolysis (9–11), a phenomenon resulting from the pleiotro-
pic adaptation of cancer cells toward a glycolytic phenotype;
(ii) the impact of variation in the distal vascular delivery of
nutrients; and (iii) the state of hypoxia (12, 13). The low pH en-
vironment stimulates cell invasion, angiogenesis, and, finally,
metastasis (14, 15).
Tumor extracellular acidosis could be a useful biomarker
for selective drug delivery, targeting, and delineation of ma-
lignancies. With the discovery of a membrane-inserting pH
(low) insertion peptide (pHLIP) that preferentially binds to
cell membranes at low extracellular pH (pHe), practical
clinical imaging and delivery of therapeutic payloads may be
possible (16–18). At normal pH, pHLIP binds as a largely
unstructured peptide at a membrane surface, but at acidic pH,
it folds and inserts across the plasma membrane as an α-helix
(19). We have previously demonstrated that pHLIP might be
useful as a PET probe with 64Cu (t1/2 ∼ 12.7 h) (20). Tumor
uptake in prostate cancer models was achieved, and related to
low pHe, but shortcomings were apparent (20). The success
of the probe as a marker of acidosis was found to have con-
trast and clearance complexities associated with the pharma-
cokinetics (PK) of pHLIP, warranting further development
efforts. Targeting of fluorescent pHLIP variants was recently
studied, and a range of potential properties was found, in-
cluding altered kinetics of insertion (21) (Scheme S1). Here,
we describe a much improved PET probe that was developed
using three strategies: modification of the (i) peptide se-
quence, (ii) radiometal, and (iii) chelate. We confirmed the lead
radiotracer’s specificity for a low pH gradient by demonstrating an
association between pHLIP-PET and pHe in different prostate
cancer models: (i) PC3-wt cells, (ii) the constitutively expressing
carbonic anhydrase IX (CAIX)-transduced PC3 cells, and
(iii) LNCaP cancer cells. Lastly, we extended our study by of-
fering a representative relationship of pHLIP with perfusion,
tumor viability, and pathways associated with acidity [i.e., lactate
via the lactate dehydrogenase A (LDH-A) protein subunit,
hypoxia, CAIX overexpression]. The probe gives useful contrast,
reveals metabolic variations within tumors, and discriminates
between necrotic and living tumor areas.
Results
Appropriate Peptide Sequence, Radionuclide, and Chelating Ligand
Modifications Can Significantly Improve pHLIP-PET Properties. We
made several modifications to reduce the nonspecific binding of
the PET probe to normal tissues to maximize contrast while
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maintaining tumor specificity. Based on reports revealing that
simple replacement of a radionuclide can significantly alter the
PK characteristics of a PET probe (22, 23), we labeled WT and
truncated versions of pHLIP from Scheme S1 with 68Ga (t1/2 ∼ 68
min) in lieu of 64Cu (t1/2 ∼ 12.7 h) with 1,4,7,10-tetraazacyclo-
dodecane-1,4,7,10-tetraacetic acid (DOTA) as chelate. Mea-
surements of the octanol/water partition coefficient (Log P)
showed that among the pHLIP variants tested, 68Ga-DOTA-WT
is the most hydrophilic (Log P ∼ −2.26 ± 0.04), whereas 68Ga-
DOTA-Var7 is the most hydrophobic (Log P ∼ −1.10 ± 0.05)
(Table S1). The binding activity (expressed as “% Bound” nor-
malized to the amount of probe added) of each radiolabeled
variant (Fig. 1) in PC3-wt cells exposed in different pH envi-
ronment showed that these peptides target cells at low pH.
Variants WT and Var7 were selected as lead compounds for
small animal PET imaging and biodistribution studies in vivo due
to their differential but favorable binding at low pH and signif-
icantly lower uptake at neutral pH, resulting in an improved
dynamic range/contrast in the pH range of interest (pH 6–7.4).
The control peptide, K-WT, showed a reverse trend, with en-
hanced binding at high pH. The lysine residues in K-WT are in
their charged form at low pH, inhibiting membrane insertion,
although in a more alkaline environment, these lysine residues
may be partially protonated, enhancing peptide–membrane
interaction (24).
68Ga-DOTA-WT vs. 68Ga-DOTA-Var7. Encouraged by the results of
our assays in vitro, we conducted in vivo experiments with s.c.
PC3-wt prostate tumor xenografts using 68Ga-DOTA-WT. Ex
vivo tissue biodistribution analysis was conducted to measure the
amount of probe bound to tumor and normal tissues to parallel
the kinetics observed in the PET images. These data (Table S2)
showed tumor uptake, expressed as the percentage of injected dose
per gram of tissue (%ID/g) at 1 h (1.87 ± 0.45%ID/g), 2 h (2.36 ±
0.40%ID/g), and 4 h (2.86 ± 0.75%ID/g) postinjection (p.i.), in
good agreement with previously reported data using 64Cu,
demonstrating probe affinity for the tumor (20). However,
nonspecific binding of 68Ga-DOTA-WT to normal tissues ob-
served in the biodistribution results (Fig. 2A and Table S2) even
at 4 h p.i. resulted in poor contrast. For example, tumor-to-
healthy tissue ratios vs. muscle (2.02 ± 1.97), blood (0.43 ± 0.16),
liver (0.40 ± 0.05), and kidneys (0.37 ± 0.16) at 4 h p.i. were
poor, necessitating further improvement (Table 1).
The shorter 68Ga-DOTA-Var7 variant was examined in the
same PC3-wt tumor model using similar methods of preparation.
Compared with the WT sequence, 68Ga-DOTA-Var7 exhibited
significantly improved properties. From the tissue distribution
(Table S3), the probe accumulation within the tumor progressed
from 2.47 ± 0.19%ID/g at 1 h p.i. to 5.60 ± 0.30%ID/g at 4 h p.i.
A direct comparative analysis between the two 68Ga-labeled
probes demonstrated a higher tumor uptake with the shorter
sequence than with the parent WT. The blood residence at 4 h p.i.
was similar; however, slightly increased nonspecific tissue binding
was demonstrated by 68Ga-DOTA-Var7 (Fig. 2A). Compared with
the WT peptide, the kidney uptake for Var7 was elevated, which
can be rationalized as resulting from faster probe clearance.
Comparing tumor-to-background ratios of both radiotracers in
Table 1, an overall increase in contrast with Var7 is seen. Based on
these observations, Var7 was chosen as the lead pHLIP variant for
further preclinical evaluation.
DOTA vs. 1,4,7-Triazacyclononane-1,4,7-Triacetic Acid. Even with
shorter variants, the residence time of pHLIP appears longer
than the physical t1/2 of
68Ga, so we reconsidered using 64Cu
to match the biological t1/2 of pHLIP better. Ex vivo bio-
distribution results (Table S4) using PC3-wt tumor-bearing mice
displayed tumor uptake at 1 h p.i. (1.19 ± 0.55%ID/g) and sig-
nificant retention after 24 h (1.64 ± 0.38%ID/g; Fig. 2B).
The blood residence activity improved with a final tumor-to-
blood ratio of 2.63 ± 0.57 at 24 h p.i. (Table 1). Despite im-
provements made on the pHLIP backbone, concerns with ra-
diotracer retention in key organs still remained. Hepatic uptake
of the radiotracer displayed unremarkable retention over 24 h
with 6.05 ± 1.36%ID/g (Fig. 2 B and C), similar to the values
reported for the 64Cu-DOTA-WT construct (4.88 ± 0.98%ID/g
at 24 h) (20); this uptake is likely to be from random scaveng-
ing of radioactive metabolites, including demetallated 64Cu in
the liver (25). The tracer distribution in the kidney revealed
only nominal reduction, even after 24 h (19.6 ± 4.0%ID/g), likely
due to the renal acidic environment (pH ∼5), which is expected
to cause binding of these pHLIP variants for a period (26),
but possibly including other effects, because it could be
improved.
Our efforts to limit indiscriminate tissue accretion of pHLIP-
PET probes led us to seek improvements of the radiometal/
chelate stability and the resistance to proteolytic degradation.
Var7 was modified with the 1,4,7-triazacyclononane-1,4,7-tri-
acetic acid (NOTA) ligand because previous reports described
superior chelate affinity for 64Cu (27, 28). In addition, we used
D-amino acids [henceforth called Var7(D)], which are known for
their resistance to enzymatic proteolysis compared with L-pep-
tidomimetics (29). In PC3-wt xenografts, no differences in tumor
accretion were seen between 64Cu-NOTA-Var7(D) (Fig. 2B and
Fig. 1. 68Ga-DOTA–labeled pHLIP variants. In vitro binding studies (n = 3)
display higher binding of 68Ga-DOTA-WT and 68Ga-DOTA-Var7 variants as
the pH of the incubation medium is decreased. Note that the opposite was
observed with the control peptide, K-WT.
Fig. 2. In vivo pharmacokinetic optimization studies in prostate tumor
xenografts. (A) Tissue distribution of 68Ga-DOTA–labeled WT and Var7
demonstrates the superiority of Var7 in terms of tumor uptake at 4 h p.i. in
PC3-wt tumor implants. (B) In the same tumor model, 64Cu-NOTA-Var7(D)
displays faster clearance and less nonspecific binding, particularly in hep-
atobiliary, intestinal, and renal tissues, in contrast to 64Cu-DOTA-Var7. Tu-
mor uptake of both probes was comparable at 24 h p.i. The PET images (C
and D) of mice bearing dual LNCaP and PC3-wt tumors demonstrate the
advantages of 64Cu-NOTA-Var7(D) compared with 64Cu-DOTA-Var7. The
tumor uptake displayed in the tables is the mean ± SD of all acquired images
(n > 3; i.e., with and without pHe measurements).
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Table S5) and the DOTA scaffold (Fig. 2B and Table S4). The
design changes in 64Cu-NOTA-Var7(D) resulted in significant
improvements. First, renal accumulation showed greatly im-
proved, exponential clearance from 13.27 ± 0.65%ID/g (1 h) to
5.84 ± 0.89%ID/g (4 h) and, finally, to 3.86 ± 1.14%ID/g (24 h).
Second, a new route of clearance, via the intestinal organs, was
found (Table S5). Third, negligible hepatic radiotracer retention
was seen at 24 h (0.88 ± 0.26%ID/g; Fig. 2B). Finally, the sig-
nificant clearance of 64Cu-NOTA-Var7(D) from healthy tissues
gave clear visualization of tumors as tumor-to-tissue contrasts
(Table 1) progressed over 24 h, for example, against blood (0.81 ±
0.22), muscle (7.81 ± 0.88), liver (1.56 ± 0.40), small intestines
(3.7 ± 1.0), and kidneys (0.39 ± 0.17). Compared with 64Cu-
DOTA-Var7 (Fig. 2C), PET images using 64Cu-NOTA-Var7(D)
acquired on mice implanted with bilateral s.c. PC3-wt (right
shoulder) and LNCaP (left shoulder) xenografts exhibited
promising PK properties (Fig. 2D) with progressive clearance of
the tracer from the liver, muscle, gut, and kidneys over 24 h,
which were key problem areas with previous pHLIP-PET probes.
Biophysical Characterization of 64Cu-NOTA-Var7(D), Our Lead
Compound. We tested the new compound, Cu-NOTA-Var7(D),
for solubility and for pH-dependent insertion to form a trans-
membrane helix. Sedimentation velocity measurements show
that Cu-NOTA-Var7(D) forms a dimer in aqueous solution at
concentrations of 7–8 μM at high and neutral pH values. The
pH-dependent changes in CD (Fig. 3A) and tryptophan fluo-
rescence signals (Fig. 3B) are similar to those observed for the
peptide with no chelate and metal (21), indicating pH-dependent
interaction of the pHLIP portion with the membrane. The ap-
parent pKa of insertion was ∼5.9 (Fig. 3C), which is slightly
higher than for the peptide alone (pKa = 5.5), probably due to
the presence of the chelate. The Log P value of 64Cu-NOTA-
Var7(D) was measured as −2.45 ± 0.13, revealing a significant
polar compound. The properties of increased solubility and el-
evation of the pK of insertion may contribute to its improved
properties in vivo.
Probe Accumulation Correlates with Acidity. We wanted to explore
disparities, if any, in the pHe of tumors with and without pHe
regulators, particularly in tumors transduced to overexpress
CAIX, a carbonic anhydrase elevated in tumor cells to cope with
high CO2 production. Thus, PC3-CAIX prostate cancer cells
were established via the transduction of PC3-wt cells with a newly
developed the retroviral vector SFG-CAIX-IRES2-GFP [retroviral
vector derived from a murine leukemia virus (SFG)-CAIX-internal
ribosomal entry site 2 (IRES2)-green fluorescent protein (GFP)]
(30). Via cell sorting, populations of GFP-expressing cells were
collected, (Fig. S1A) and Western blots confirmed higher CAIX
expression in PC3-CAIX cells than in the WT cells under normal
oxygenated conditions [20% (vol/vol) O2] (Fig. S1B).
The intrinsic acidity of the three prostate xenografts (PC3-wt,
PC3-CAIX, and LNCaP) was evaluated by measuring pHe and
intracellular pH (pHi) via 1H-decoupled 31P magnetic resonance
spectroscopy (MRS) using 3-aminopropylphosphonate (3-APP)
(Fig. 4A). Each of the three tumor models exhibited a lower
whole-tumor pHe (Fig. 4B) than its whole-tumor pHi (Fig. 4C),
in concordance with previous studies (31–34). Of all of the tumor
models, LNCaP tumors had the highest pHi (7.28 ± 0.07) and
pHe (7.07 ± 0.04), whereas the PC3-wt xenografts exhibited the
lowest pHi (6.94 ± 0.07) and pHe (6.93 ± 0.03). In contrast to
the WT model, the CAIX-enhanced tumor implants displayed an
alkaline-shifted pHi (7.26 ± 0.09, P = 0.012) and pHe (7.07 ±
0.06, P = 0.035). Analysis of the ΔpH (pHi − pHe) of these
tumors revealed similar proton fluxes in LNCaP (0.27 ± 0.10, P =
0.020) and PC3-CAIX (0.33 ± 0.13, P = 0.018), establishing
greater extracellular acidification gradients in these two xeno-
grafts than in PC3-wt (−0.010 ± 0.055) (Fig. 4D).
Uptake of 64Cu-NOTA-Var7(D) correlates inversely with pHe
when data from all three tumor models are taken into account.
Each mouse used for pH MRS measurements was also used for
PET and biodistribution experiments, giving greater confidence
in the correlations (pairing details are provided in Table S6). In
the plot of pHe vs. 64Cu-NOTA-Var7(D) uptake (PET imaging at
1 h p.i. and 24-h ex vivo tissue sampling radioactivity assays) for
PC3-wt tumors (Fig. 5A), incremental accumulation of the ra-
diotracer is seen as the tumor acidity increases. By pooling all data
points from all three prostate xenografts (Fig. 5B), threshold limits
can be established, showing that a tumor pHe <6.9 provides high
probe localization (>3.0%ID/g), whereas a pHe range of 6.9–7.4
results in lower probe uptake (<3.0%ID/g).
Ex Vivo Autoradiography Demonstrates pHLIP Accumulation in Tumor
Regions Associated with Elevated Metabolism. Histological staining
was used to examine viability and metabolic features of the
tissues that stain or do not stain with the probe. Fig. 6 A–C shows
the distribution of 64Cu-NOTA-Var7(D) (autoradiography) and
correlative histological markers pimonidazole (green, hypoxia),
Hoechst 33342 (blue, vascular perfusion), and LDH-A (red) in
representative PC3-CAIX (Fig. 6 A–C, Top), LNCaP (Fig. 6 A–C,
Middle), and PC3-wt (Fig. 6 A–C, Bottom) tumors. Histological
Table 1. Tumor-to-background tissue contrast ratios [mean ± SD (rel. u.)] obtained for the
68Ga-labeled WT and Var7 variants at 4 h p.i. and for 64Cu-Var7 with either DOTA or NOTA as
a ligand at 24 h p.i
T/B 68Ga-DOTA-WT 68Ga-DOTA-Var7 64Cu-DOTA-Var7 64Cu-NOTA-Var7(D)
Tumor/blood 0.43 ± 0.16 0.69 ± 0.18 2.63 ± 0.57 0.81 ± 0.22
Tumor/liver 0.40 ± 0.05 0.61 ± 0.15 0.28 ± 0.08 1.56 ± 0.40
Tumor/kidney 0.37 ± 0.16 0.02 ± 0.01 0.08 ± 0.01 0.39 ± 0.17
Tumor/muscle 2.02 ± 1.97 3.17 ± 0.91 7.81 ± 1.78 7.81 ± 0.88
Tumor/bone 0.25 ± 0.13 0.57 ± 0.41 1.94 ± 0.41 6.04 ± 2.34
Absolute uptake values are listed in Table S2 for 68Ga-DOTA-WT, Table S3 for 68Ga-DOTA-Var7, Table S4 for
64Cu-DOTA-Var7, and Table S5 for 64Cu-NOTA-Var7(D). rel. u., relative units; T/B, tumor-to-background tissue.
Fig. 3. pH-dependent interaction of Cu-NOTA-Var7(D) with the lipid
membrane bilayer. Cold Cu-NOTA-Var7(D) was studied for the presence of
the three basic states of pHLIP: State I is the peptide in solution at pH 8, state
II is the peptide in the presence of 1-palmitoyl-2-oleoyl-sn-glycero-3-phos-
phocholine (POPC) liposomes at pH 8, and state III is the folding and in-
sertion of the peptide with POPC liposomes from pH 8–3.6. The states were
monitored by changes of the steady-state CD (A) and tryptophan fluores-
cence spectroscopy at λex = 295 nm (B). (C) Changes in the intrinsic fluo-
rescence were monitored as a function of pH wherein a pKa of ∼5.9 was
obtained. λmax, maximum wavelength.
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stains (H&E) were also conducted to determine tumor tissue
viability (Fig. S2). In all tumors, the 64Cu-NOTA-Var7(D) dis-
tribution is heterogeneous, with increasing accumulation seen in
perinecrotic, hypoxic tumor regions. Binding of 64Cu-NOTA-
Var7(D) is also observed in animal skin, an inherent acidic tis-
sue, as indicated by the red arrows on the tumor sections in Fig.
6B. Fig. S3 A–C contains rebinned scatterplots of the relative
pixel intensity values of the images shown in Fig. 6 A–C, re-
spectively. In all cases, the regions of highest 64Cu-NOTA-Var7(D)
uptake corresponded with regions of highest pimonidazole and
LDH-A staining, with the converse lowest 64Cu-NOTA-Var7(D)
uptake corresponding to the regions of lowest LDH-A expres-
sion and pimonidazole uptake. There appeared to be no
relationship between Hoechst 33342 staining intensity and 64Cu-
NOTA-Var7(D) uptake. Thus, we find that probe uptake is
correlated with hypoxia and LDH-A.
Discussion
By creating a useful probe for imaging tumor acidosis, we enable
assessment of a universal trait associated with tumor invasiveness
in most malignancies. We illustrate the improvements made to-
ward better PK and dosimetric properties of pHLIP as a non-
invasive PET radiotracer. More importantly, this probe was able
to distinguish highly acidic tumors, with a direct association to
tumor pHe. Furthermore, we extended our efforts at un-
derstanding the mechanism of uptake of this probe through
autoradiographic and histological studies of all three tumor
models to provide insights on its target.
Based on a set of observations with earlier pHLIP-based
probes, we were able to design a new version that should prove
useful in clinical applications. The Var7 variant sequence of
pHLIP proved to offer faster clearance and tumor delivery than
the parent pHLIP; however, its prolonged residence in healthy
tissue, paired with the short physical t1/2 of
68Ga, was mis-
matched, and degradation of the peptide was suspected. To cope
with these issues, we synthesized the peptide from D-amino acids
and revisited the use of 64Cu, which has a longer t1/2, to allow
clearance of the probe from healthy tissue. The relatively poor
chelating properties of DOTA for 64Cu had resulted in accu-
mulation of unbound Cu in tissues (i.e., liver) (25), so we
searched for a better chelation group, deciding on NOTA. This
set of design choices gave us 64Cu-NOTA-Var7(D). The superiority
of NOTA to DOTA is clear in the comparisons of biodistribution,
tumor-to-tissue contrast ratios, and PET imaging (Fig. 2 C and D
and Tables S4 and S5). A much lower uptake is seen in the liver,
intestines, spleen, and kidneys, resulting in improved contrast ratios
between these tissues and the tumor. We now have a workable
probe to develop for clinical use.
Our results differ in some respects from those reported earlier.
In our hands, in a comparison of two of the tumor models
(LNCaP and PC3-wt) in the right shoulder of athymic nude mice,
the pHe showed a trend opposite to that observed by Vavere et al.
(20). Those investigators also used LNCaP and PC3, but for
tumors implanted in the flanks of athymic nu/nu mice and for
tumor volumes >500 mm3, so the observed differences may po-
tentially be due to the smaller tumor size (<400 mm3) used in our
study and the differences in tumor location (shoulder vs. flank).
Our goal was to use tumors with only moderate necrosis for the
best comparison with tumors seen in the clinic; hence, our choice
of small- to medium-sized tumors. Further, we used
1H-decoupled 31P MRS, which may influence the average chem-
ical shift of 3-APP, because without 1H decoupling, the signal
shape and width are not only determined by T2 relaxation and the
pHe tissue distribution but also by the multiplet structure of 3-APP
(35). We did not find a significant relationship between tumor size
and pHe for tumors <400 mm3 (Table S6), which is consistent with
the data by Raghunand et al. (34), in which tumoral pH was ob-
served to decrease over a tumor size range of ∼200—1,500 mm3,
although not significantly decreasing in smaller tumors (<400
mm3). Although decreases of mean tumor pHe and pHi with
increasing tumor size have been observed in rodent tumors
when measured over a large tumor size range (32, 34), both
decreasing pH with increasing tumor size and a lack of such
a relationship have been reported in human tumors (36).
In retrospect, we find that the outcomes of measuring pH as
an average do not give a true representation of tumor acidity, as
evidenced by the broad pH distributions observed from 31P
MRS. Instead, details of pH variation within a tumor may be key,
even at the cellular level. Variations in the spatial distribution of
pHe have been reported such that gradients exist at the interface
of the cellular membrane and cytosol (37, 38), prompting us to
examine the differences between cytosolic and extracellular pH
and to derive the net proton flux (although we still needed to use
average values). We observed that the transduced PC3-CAIX
and LNCaP implants had greater pHe gradients (ΔpH) than the
WT (PC3-wt) model; however, the measured pHe values of the
two models followed an opposite trend from the ΔpH values. We
rationalize that these contrasting measurements may be due to
the vast heterogeneity in tumor homeostasis and development,
which is governed by an intricate mesh of metabolic pathways,
including rate of glycolytic metabolism, expression of acid-
extruding protein, and diverse buffering capacities and O2
Fig. 4. In vivo pHe measurements. (A) Representative 1H-decoupled 31P MR
spectrum of a PC3-CAIX tumor after 3-APP injection, where 3-APP, phos-
phoethanolamine (PE), phosphocholine (PC), Pi, phosphocreatine (PCr), NDP/
NTPs. (B) pHe measurements show PC3-wt as the most acidic (6.93 ± 0.03; P =
0.035) compared with the PC3-CAIX (7.07 ± 0.06) and LNCaP (7.07 ± 0.04)
xenografts. (C) Intracellular acidity of PC3-wt (6.94 ± 0.07; P = 0.012) is
higher than that of the other prostate implants. (D) Positive proton fluxes
are observed for PC3-CAIX (0.33 ± 0.13, n = 5; P = 0.018) and LNCaP (0.27 ±
0.10, n = 5; P = 0.020) tumors, but not for PC3-wt tumors (−0.010 ± 0.055,
n = 5) (D). a.u., absorbance units.
Fig. 5. pHLIP-PET shows a direct association with extracellular acidity. (A)
64Cu-NOTA-Var7(D) tumor uptake is shown to increase as the pHe of the
PC3-wt tumor model decreases. (B) Plot of the pHe against radiotracer tumor
uptake (24 h p.i.) from all three tumor models demonstrates a notable
threshold where higher probe accretion (>3%ID/g) correlates to an acidic
extracellular space with pHe <6.9. Because of tumor heterogeneity even
within the same xenograft model, each measured tumor is treated as
a separate data point.
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concentrations in the blood vessel network, just to name a few
factors (36, 39). Despite these uncertainties, we observed a cor-
relation of targeting with absolute pHe, where, at a pHe <6.9,
higher tumor accumulation of the radiotracer was observed, with
>3%ID/g. However, at a pHe >6.9, measuring and imaging tu-
mor acidity using this probe is poorly resolved. We postulate that
this incident may be an effect of the insertion pKa of the full
construct (pKa ∼ 5.9).
The development and use of pHLIP variants with higher and
lower pKas of insertion across cellular membranes, combined
with favorable thermodynamics and kinetics properties, would
allow measurement of a wider dynamic range of potential pHe
probed by pHLIP technology. Also, pHLIP variants tuned over
a pKa range could expand the applicability of minimally invasive
pH measurements to applications beyond cancer. Thus, pHLIP-
based acidosis imaging probes may offer a relative read-out of
distributions of pHe, which may, in turn, allow clinical analysis of
tumor invasiveness and regionalization. As we move forward,
associating pHLIP tumor uptake with tumor acidosis using a re-
gional pHe map is deemed more appropriate; these studies are
currently underway.
Autoradiography and histology performed on excised tumor
sections revealed a heterogeneous distribution of 64Cu-NOTA-
Var7(D) within the tumors, again emphasizing the need to avoid
gross averaging of pH measurements solely to correlate the
target(s) of our probe with markers related to acidity. We used
pimonidazole (a hypoxia tracer) and LDH-A (involved in the
interconversion of pyruvate and lactate) (40) as markers for
comparison with the pHLIP distribution, in the absence of a di-
rect histological marker of low pHe. 64Cu-NOTA-Var7(D) lo-
calization appears preferentially in perinecrotic regions (Fig. S2)
that display high uptake of the hypoxia marker pimonidazole but
shows no clear relationship with the vascular perfusion marker
Hoechst 33342 (Fig. S3). Elevated LDH-A would be expected to
result in concomitant elevated pHLIP binding, which we have
observed in all three tumor models (Fig. S3).
Our data demonstrate that in the tumor models used in this
study, LDH-A expression and pimonidazole binding (primarily
dependent on low pO2) (41) have similar but discordant spatial
distributions, in good agreement with previous reports that lactic
acidosis and hypoxia are not always interdependent (9, 38, 39). It
is likely that tumor regions of poor vascularity and low pO2 will
also possess excess extracellular H+ ions due to anaerobic glu-
cose metabolism and local lactic acidosis. Although we observed
a trend toward increasing 64Cu-NOTA-Var7(D) uptake with
increasing pimonidazole uptake, the relationship appears to be
nonlinear (Fig. S3 A–C). This observation may be due, in part, to
the effect of pHe on absolute pimonidazole uptake, although this
observation is likely to be a minor effect over the pHe ranges
measured in this study (42).
CAIX expression, which can be taken to indicate regions of
lowered pHe, is similarly regulated by HIF-1 transcription factor
and has a cellular t1/2 in the order of days (43). Although argu-
ably inversely related to lowered pHe, CAIX expression cannot
be assumed to relate to absolute pHe linearly. Taken together
with the induced, constitutive expression in the PC3-CAIX
model and the very low observed CAIX expression in the LNCaP
model, these facts render CAIX an unsuitable marker for low
pHe or pO2 in our study.
By finding a probe that marks the acidosis inherent in tumor
metabolism, we have defined a clinical potential for marking
tumors and measuring their aggressive characteristics. Defining
a probe with usable imaging properties could allow it to be used
to follow the progression of a tumor and to monitor the effects
of therapy.
Methods
Additional details of materials, methods, and equipment can be found in SI
Methods.
Radiochemistry. Variants of pHLIP were purchased from C. S. Bio Co., Inc. and
derivatized with either maleimido-monoamide-DOTA (Macrocyclics, Inc.) or
p-SCN-Bn-NOTA (Macrocyclics, Inc.). Radiolabeling of pHLIP-DOTA or pHLIP-
NOTA with 68Ga or 64Cu was conducted via a microwave-assisted reaction at
90 °C for 1 min in 0.5 M ammonium acetate (pH ∼5.5). Unbound radiometal
was removed via a C18 solid-phase extraction cartridge (Grace). The pure
labeled peptide was eluted with 0.5% 2 M HCl in ethanol. Radiochemical
purities of >95% were ensured before administration to animals.
In Vitro Cell Binding. PC3-wt cells were incubated with different 68Ga-labeled
pHLIP-DOTA variants for 1 h at 37 °C at different pH values ranging from
∼6.3 to 7.0. The cells were then washed twice with the same media used for
incubation to remove unbound activity, and the retained activity was
counted using a Wizard2 2480 gamma counter (PerkinElmer).
pH Dependence. ThepH-dependent partitioningof thepeptides into lipid bilayers
using 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine liposomes was investi-
gatedbymeasuring the shift of the intrinsic fluorescence spectralmaximumof the
peptide as the pH is lowered from pH 8 to pH 2, as previously described (21).
Steady-State Fluorescence and CD Measurements. Tryptophan fluorescence
and CD measurements were carried out on a PC1 ISS spectrofluorometer (ISS,
Inc.) and a MOS-450 spectrometer (Biologic, Inc.), respectively, at 25 °C, as
previously reported (21).
Partition Coefficient. The Log P values (n = 3) were determined for each la-
beled peptide by measuring the amount of activity from an equal volume of
samples obtained from the octanol and 1× PBS (pH ∼7) layers.
Cell Transduction. Stable clones of PC3-CAIX were developed by transducing
PC3-wt cells with SFG-CAIX-IRES2-GFP. PC3-wt cells at ∼50% confluence were
incubated with virus-containing medium for 12 h in the presence of Poly-
brene (8 mg/mL; Sigma) as previously described (44). Cells were sorted sev-
eral times using a FACS (BD Bioscience) (Fig. S1A), with Western blot
experiments confirming CAIX expression (Fig. S1B).
Animal Models. All animals were treated according to the guidelines set and
approved by the Research Animal Resource Center and Institutional Animal
Care and Use Committee at Memorial Sloan–Kettering Cancer Center. Tumors
were induced in male, athymic nu/nu mice (Taconic Farms, Inc. or Harlan
Laboratories) on the shoulder by s.c. injection of 3 × 106 million cells of PC3-wt,
PC3-CAIX, or LNCaP cells in a 200-μL suspension of 1:1 media/Matrigel Base-
ment Membrane Matrix (BD Sciences). Mice were used once tumor volumes
reached 150–300 mm3.
Fig. 6. Histology and autoradiography. 64Cu-NOTA-Var7(D) autoradiography
(24 h p.i.) and correlative histology from 10-μm adjacent sections obtained
from PC3-CAIX (A), LNCaP (B), and PC3-wt (C) tumors. The distributions of
64Cu-NOTA-Var7(D) (white), pimonidazole (hypoxia, green), and Hoechst
33342 (perfusion, blue), as well as the expression of LDH-A (red), are shown.
White arrows indicate discordance between pimonidazole uptake and LDH-A
expression, whereas red arrows mark skin accumulation of the imaging probe.
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In Vivo Animal PET Imaging and Biodistribution. Mice (n = 3–5) were injected
i.v. with 68Ga/64Cu-pHLIP variants (200–300 μCi, 15–25 μg for imaging and
20–50 μCi, 1–2 μg for biodistribution) in 100–200 μL of 0.9% saline formulations.
Imaging experiments were recorded with a microPET Focus 120 or R4 scanner
(Concorde Microsystems) at 1–24 h p.i., while the mice were anesthetized with
1.5–2.0% isoflurane (Baxter Healthcare) in air. The images were analyzed for
regions of interest (ASIPro VM; Concorde Microsystems). Biodistribution studies
were conducted after the mice were killed via CO2 asphyxiation 1–24 h p.i. The
%ID/g was calculated as the activity bound to the tissue per organ weight per
actual injected dose and was decay-corrected to the time of counting. For
studies demonstrating correlation of extracellular acidification and pHLIP-PET,
pH, PET imaging, and biodistribution measurements were conducted on the
same tumors. Using the same mice, 64Cu-NOTA-Var7(D) was administered i.v.
post-MRS. PET images were acquired at 1–24 h p.i., with the mice subsequently
euthanized after the last scan for ex vivo tissue analysis. Pairing of tumors is
detailed in Table S6.
In Vivo pH Measurements by 1H-Decoupled 31P MRS. TheMRS experiments were
performed on a horizontal-bore 7-T MR spectrometer (Bruker) using a home-
built 1H/31P magnetic resonance (MR) coil assembly, using previous methods
(35, 45) (SI Methods). The MR spectra were fitted in the time domain, using
the software XsOsNMR (kindly provided by Dr. Dikoma Shungu and Xiaoling
Mao, Cornell University, New York). The intracellular and extracellular pH
(pHi, pHe) were calculated from the chemical shifts (δ) of inorganic phosphate
(Pi) and 3-aminopropylphosphonate (3-APP) relative to α-NTP at −10.05 ppm,
respectively, using their respective Henderson-Hasselbalch equations (SI
Methods) as described previously (35). As Pi is predominantly intracellular
(45), the resulting calculated pH represents the pHi (35). The pH values were
reported as the mean ± SEM.
Statistical Analysis. Data values were expressed as the mean ± SD unless
otherwise stated. Statistical analysis was performed with GraphPad Prism
version 5.03 software using the Student t test. A P value of <0.05 is con-
sidered statistically significant.
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